Sep 2, 2026 · 6 min · 7 segments
The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first…
Briana ClarkHost
In our top story, Nycox and its partner, COA, have announced that the FDA has accepted the company's new drug application for NCX-470, an investigational eyedrop for glaucoma.
NCX-470 is a nitric oxide donating by Matapras eyedrop being developed to lower IOP in patients with open-angle glaucoma or ocular hypertension.
According to NICOX, the trials demonstrated clinically meaningful IOP reductions of up to 10 millimeters of mercury with a favorable safety profile.
If approved, the companies plan to commercially launch the iDrop in the second half of 2027.
In our top story, Nycox and its partner, COA, have announced that the FDA has accepted the company's new drug application for NCX-470, an investigational eyedrop for glaucoma.
NCX-470 is a nitric oxide donating by Matapras eyedrop being developed to lower IOP in patients with open-angle glaucoma or ocular hypertension.
According to NICOX, the trials demonstrated clinically meaningful IOP reductions of up to 10 millimeters of mercury with a favorable safety profile.
If approved, the companies plan to commercially launch the iDrop in the second half of 2027.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
